Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon May 27, 2022 12:00pm

203 Views

Post# 34712344

Well Well

The Company’s lack of financial resources has also impacted the Company’s research and development activities and has resulted in the Company placing the Phase 1 clinical study of R-107 on hold. The Company will not be able to complete the Annual Documents and Q1 Filings, nor will it be able to re-start the Phase 1 clinical study of R-107, until it raises additional capital.

The Company is seeking to raise additional capital and is working to do so with a U.S. based firm that advises clients on private debt, equity capital and M&A transactions.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages